Published in Chem Biol on October 01, 2007
A complex task? Direct modulation of transcription factors with small molecules. Curr Opin Chem Biol (2010) 1.75
CBFbeta is critical for AML1-ETO and TEL-AML1 activity. Blood (2009) 1.74
Chemical biology. A small-molecule inhibitor of the aberrant transcription factor CBFβ-SMMHC delays leukemia in mice. Science (2015) 1.60
Computational design of a PDZ domain peptide inhibitor that rescues CFTR activity. PLoS Comput Biol (2012) 1.40
Assemblages: functional units formed by cellular phase separation. J Cell Biol (2014) 1.30
Protein design using continuous rotamers. PLoS Comput Biol (2012) 1.30
Binding of a small molecule at a protein-protein interface regulates the chaperone activity of hsp70-hsp40. ACS Chem Biol (2010) 1.28
OSPREY: protein design with ensembles, flexibility, and provable algorithms. Methods Enzymol (2013) 1.20
Features of protein-protein interactions that translate into potent inhibitors: topology, surface area and affinity. Expert Rev Mol Med (2012) 1.18
Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography. J Med Chem (2009) 1.12
Dead-end elimination with perturbations (DEEPer): a provable protein design algorithm with continuous sidechain and backbone flexibility. Proteins (2012) 1.11
Posttranslational modifications of RUNX1 as potential anticancer targets. Oncogene (2014) 1.00
Expression of RUNX1 correlates with poor patient prognosis in triple negative breast cancer. PLoS One (2014) 0.98
Transforming activity of AML1-ETO is independent of CBFbeta and ETO interaction but requires formation of homo-oligomeric complexes. Proc Natl Acad Sci U S A (2009) 0.96
The Runx transcriptional co-activator, CBFbeta, is essential for invasion of breast cancer cells. Mol Cancer (2010) 0.95
Accelerated leukemogenesis by truncated CBF beta-SMMHC defective in high-affinity binding with RUNX1. Cancer Cell (2010) 0.91
Effective targeting of STAT5-mediated survival in myeloproliferative neoplasms using ABT-737 combined with rapamycin. Leukemia (2010) 0.88
Targeting protein-protein interactions in hematologic malignancies: still a challenge or a great opportunity for future therapies? Immunol Rev (2015) 0.88
Automated NMR Assignment and Protein Structure Determination using Sparse Dipolar Coupling Constraints. Prog Nucl Magn Reson Spectrosc (2009) 0.87
Protein loop closure using orientational restraints from NMR data. Proteins (2011) 0.86
Characterization of RNA aptamers that disrupt the RUNX1-CBFbeta/DNA complex. Nucleic Acids Res (2009) 0.86
Small Molecule Inhibitor of CBFβ-RUNX Binding for RUNX Transcription Factor Driven Cancers. EBioMedicine (2016) 0.86
Structure of the AML1-ETO NHR3-PKA(RIIα) complex and its contribution to AML1-ETO activity. J Mol Biol (2010) 0.83
JMJD1C is required for the survival of acute myeloid leukemia by functioning as a coactivator for key transcription factors. Genes Dev (2015) 0.82
BWM*: A Novel, Provable, Ensemble-based Dynamic Programming Algorithm for Sparse Approximations of Computational Protein Design. J Comput Biol (2016) 0.80
Compact Representation of Continuous Energy Surfaces for More Efficient Protein Design. J Chem Theory Comput (2015) 0.80
An efficient parallel algorithm for accelerating computational protein design. Bioinformatics (2014) 0.79
Direct and Propagated Effects of Small Molecules on Protein-Protein Interaction Networks. Front Bioeng Biotechnol (2015) 0.78
Computer applications for prediction of protein-protein interactions and rational drug design. Adv Appl Bioinform Chem (2009) 0.77
CBFβ and the leukemogenic fusion protein CBFβ-SMMHC associate with mitotic chromosomes to epigenetically regulate ribosomal genes. J Cell Biochem (2014) 0.77
Fast gap-free enumeration of conformations and sequences for protein design. Proteins (2015) 0.77
comets (Constrained Optimization of Multistate Energies by Tree Search): A Provable and Efficient Protein Design Algorithm to Optimize Binding Affinity and Specificity with Respect to Sequence. J Comput Biol (2016) 0.77
New agents for AML and MDS. Best Pract Res Clin Haematol (2009) 0.76
Fast search algorithms for computational protein design. J Comput Chem (2016) 0.76
Parallel Computational Protein Design. Methods Mol Biol (2017) 0.75
A Small Covalent Allosteric Inhibitor of Human Cytomegalovirus DNA Polymerase Subunit Interactions. ACS Infect Dis (2016) 0.75
OSPREY Predicts Resistance Mutations Using Positive and Negative Computational Protein Design. Methods Mol Biol (2017) 0.75
Challenges in cancer molecular targets and therapeutics. Front Oncol (2011) 0.75
A critical analysis of computational protein design with sparse residue interaction graphs. PLoS Comput Biol (2017) 0.75
Protein-ligand structure guided by backbone and side-chain proton chemical shift perturbations. J Biomol NMR (2014) 0.75
Runx1 is required for the endothelial to haematopoietic cell transition but not thereafter. Nature (2009) 5.34
Runx1 expression marks long-term repopulating hematopoietic stem cells in the midgestation mouse embryo. Immunity (2002) 4.15
Of lineage and legacy: the development of mammalian hematopoietic stem cells. Nat Immunol (2008) 4.04
Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. Blood (2005) 3.32
DNA specificity determinants associate with distinct transcription factor functions. PLoS Genet (2009) 2.56
The DCX-domain tandems of doublecortin and doublecortin-like kinase. Nat Struct Biol (2003) 2.22
PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis. Nat Genet (2007) 2.18
A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma. Nat Med (2009) 2.17
The tetramer structure of the Nervy homology two domain, NHR2, is critical for AML1/ETO's activity. Cancer Cell (2006) 2.09
Core-binding factors in hematopoiesis and immune function. Oncogene (2004) 2.04
Structure of the MLL CXXC domain-DNA complex and its functional role in MLL-AF9 leukemia. Nat Struct Mol Biol (2009) 1.98
NMR solution structure of the integral membrane enzyme DsbB: functional insights into DsbB-catalyzed disulfide bond formation. Mol Cell (2008) 1.92
The allantois and chorion, when isolated before circulation or chorio-allantoic fusion, have hematopoietic potential. Development (2006) 1.88
Computational structure-based redesign of enzyme activity. Proc Natl Acad Sci U S A (2009) 1.77
Probabilistic disease classification of expression-dependent proteomic data from mass spectrometry of human serum. J Comput Biol (2003) 1.76
Erythroid/myeloid progenitors and hematopoietic stem cells originate from distinct populations of endothelial cells. Cell Stem Cell (2011) 1.76
CBFbeta is critical for AML1-ETO and TEL-AML1 activity. Blood (2009) 1.74
Site-directed parallel spin-labeling and paramagnetic relaxation enhancement in structure determination of membrane proteins by solution NMR spectroscopy. J Am Chem Soc (2006) 1.73
Core binding factors are necessary for natural killer cell development and cooperate with Notch signaling during T-cell specification. Blood (2008) 1.67
A novel ensemble-based scoring and search algorithm for protein redesign and its application to modify the substrate specificity of the gramicidin synthetase a phenylalanine adenylation enzyme. J Comput Biol (2005) 1.66
Neuroleukemiosis: case report of leukemic nerve infiltration in acute lymphoblastic leukemia. Muscle Nerve (2008) 1.66
Structural basis for the inhibition of the essential Plasmodium falciparum M1 neutral aminopeptidase. Proc Natl Acad Sci U S A (2009) 1.63
Charged gels as orienting media for measurement of residual dipolar couplings in soluble and integral membrane proteins. J Am Chem Soc (2004) 1.63
Whole-mount three-dimensional imaging of internally localized immunostained cells within mouse embryos. Nat Protoc (2012) 1.58
Optimal mutation sites for PRE data collection and membrane protein structure prediction. Structure (2011) 1.55
The minimized dead-end elimination criterion and its application to protein redesign in a hybrid scoring and search algorithm for computing partition functions over molecular ensembles. J Comput Chem (2008) 1.55
Trisomy 21-associated defects in human primitive hematopoiesis revealed through induced pluripotent stem cells. Proc Natl Acad Sci U S A (2012) 1.54
High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition. PLoS One (2010) 1.54
MLL protects CpG clusters from methylation within the Hoxa9 gene, maintaining transcript expression. Proc Natl Acad Sci U S A (2008) 1.50
VMY-1-103, a dansylated analog of purvalanol B, induces caspase-3-dependent apoptosis in LNCaP prostate cancer cells. Cancer Biol Ther (2010) 1.49
AMP-activated protein kinase promotes human prostate cancer cell growth and survival. Mol Cancer Ther (2009) 1.48
Attenuation of AML1-ETO cellular dysregulation correlates with increased leukemogenic potential. Blood (2013) 1.46
Therapeutic approaches targeting prostate cancer progression using novel voltage-gated ion channel blockers. Clin Prostate Cancer (2003) 1.44
Disease mutations in RUNX1 and RUNX2 create nonfunctional, dominant-negative, or hypomorphic alleles. EMBO J (2007) 1.44
Structural basis for recognition of SMRT/N-CoR by the MYND domain and its contribution to AML1/ETO's activity. Cancer Cell (2007) 1.43
Predicting resistance mutations using protein design algorithms. Proc Natl Acad Sci U S A (2010) 1.41
Computational design of a PDZ domain peptide inhibitor that rescues CFTR activity. PLoS Comput Biol (2012) 1.40
The core-binding factor beta subunit is required for bone formation and hematopoietic maturation. Nat Genet (2002) 1.36
Voltage-sensitive ion channels and cancer. Cancer Metastasis Rev (2006) 1.34
Algorithm for backrub motions in protein design. Bioinformatics (2008) 1.33
Penetratin and related cell-penetrating cationic peptides can translocate across lipid bilayers in the presence of a transbilayer potential. Biochemistry (2003) 1.33
Structure determination of symmetric homo-oligomers by a complete search of symmetry configuration space, using NMR restraints and van der Waals packing. Proteins (2006) 1.32
Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia. Blood (2012) 1.31
Dead-end elimination with backbone flexibility. Bioinformatics (2007) 1.30
Protein design using continuous rotamers. PLoS Comput Biol (2012) 1.30
Predicting new indications for approved drugs using a proteochemometric method. J Med Chem (2012) 1.29
Leukemia and hematopoietic stem cells: balancing proliferation and quiescence. Cell Cycle (2008) 1.28
The expression of Sox17 identifies and regulates haemogenic endothelium. Nat Cell Biol (2013) 1.28
Mechanisms of unphosphorylated STAT3 transcription factor binding to DNA. J Biol Chem (2012) 1.25
Runx1 function in hematopoiesis is required in cells that express Tek. Blood (2005) 1.25
Sazetidine-A, a selective alpha4beta2 nicotinic receptor desensitizing agent and partial agonist, reduces nicotine self-administration in rats. J Pharmacol Exp Ther (2009) 1.24
The protein-small-molecule database, a non-redundant structural resource for the analysis of protein-ligand binding. Bioinformatics (2009) 1.24
Runx1 deletion or dominant inhibition reduces Cebpa transcription via conserved promoter and distal enhancer sites to favor monopoiesis over granulopoiesis. Blood (2012) 1.22
Plasmodium falciparum neutral aminopeptidases: new targets for anti-malarials. Trends Biochem Sci (2009) 1.21
Runx1 is expressed in adult mouse hematopoietic stem cells and differentiating myeloid and lymphoid cells, but not in maturing erythroid cells. Stem Cells (2004) 1.21
Effects of sazetidine-A, a selective alpha4beta2 nicotinic acetylcholine receptor desensitizing agent on alcohol and nicotine self-administration in selectively bred alcohol-preferring (P) rats. Psychopharmacology (Berl) (2010) 1.20
OSPREY: protein design with ensembles, flexibility, and provable algorithms. Methods Enzymol (2013) 1.20
STAT3 suppresses transcription of proapoptotic genes in cancer cells with the involvement of its N-terminal domain. Proc Natl Acad Sci U S A (2013) 1.20
The binding of the PDZ tandem of syntenin to target proteins. Biochemistry (2006) 1.19
High resolution structure of the HDGF PWWP domain: a potential DNA binding domain. Protein Sci (2005) 1.19
Leukemia fusion target AF9 is an intrinsically disordered transcriptional regulator that recruits multiple partners via coupled folding and binding. Structure (2012) 1.18
Increasing the accuracy of solution NMR structures of membrane proteins by application of residual dipolar couplings. High-resolution structure of outer membrane protein A. J Am Chem Soc (2006) 1.18
Crystal structure of menin reveals binding site for mixed lineage leukemia (MLL) protein. J Biol Chem (2011) 1.16
Phylogenetic classification of protozoa based on the structure of the linker domain in the bifunctional enzyme, dihydrofolate reductase-thymidylate synthase. J Biol Chem (2003) 1.16
RUNX1 mutations in clonal myeloid disorders: from conventional cytogenetics to next generation sequencing, a story 40 years in the making. Crit Rev Oncog (2011) 1.15
Characterization of the Plasmodium falciparum M17 leucyl aminopeptidase. A protease involved in amino acid regulation with potential for antimalarial drug development. J Biol Chem (2006) 1.15
Enhanced expression of SOS1 is detected in prostate cancer epithelial cells from African-American men. Int J Oncol (2009) 1.13
Design, synthesis and evaluation of novel hydroxyamides as orally available anticonvulsants. Bioorg Med Chem (2004) 1.13
Endothelio-mesenchymal interaction controls runx1 expression and modulates the notch pathway to initiate aortic hematopoiesis. Dev Cell (2013) 1.13
Improved Pruning algorithms and Divide-and-Conquer strategies for Dead-End Elimination, with application to protein design. Bioinformatics (2006) 1.12
Redesigning the PheA domain of gramicidin synthetase leads to a new understanding of the enzyme's mechanism and selectivity. Biochemistry (2006) 1.12
Energetic contribution of residues in the Runx1 Runt domain to DNA binding. J Biol Chem (2003) 1.12
T-lymphoid, megakaryocyte, and granulocyte development are sensitive to decreases in CBFbeta dosage. Blood (2006) 1.11
Dead-end elimination with perturbations (DEEPer): a provable protein design algorithm with continuous sidechain and backbone flexibility. Proteins (2012) 1.11
Hematopoietic stem cell emergence in the conceptus and the role of Runx1. Int J Dev Biol (2010) 1.11
A structure-based approach for mapping adverse drug reactions to the perturbation of underlying biological pathways. PLoS One (2010) 1.10
Structure, dynamics and function of the outer membrane protein A (OmpA) and influenza hemagglutinin fusion domain in detergent micelles by solution NMR. FEBS Lett (2003) 1.09
Structure of the Plasmodium falciparum M17 aminopeptidase and significance for the design of drugs targeting the neutral exopeptidases. Proc Natl Acad Sci U S A (2010) 1.09
CBFbeta allosterically regulates the Runx1 Runt domain via a dynamic conformational equilibrium. Nat Struct Mol Biol (2004) 1.08
Structure-based discovery of a boronic acid bioisostere of combretastatin A-4. Chem Biol (2005) 1.07